Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q19596938> ?p ?o }
Showing triples 1 to 38 of
38
with 100 triples per page.
- Q19596938 subject Q8533689.
- Q19596938 subject Q9052323.
- Q19596938 abstract "Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.".
- Q19596938 atcPrefix "None".
- Q19596938 casNumber "872363-17-2".
- Q19596938 iupacName "6-Fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine".
- Q19596938 pubchem "44557636".
- Q19596938 thumbnail Dipraglurant.svg?width=300.
- Q19596938 wikiPageExternalLink dipra-er.
- Q19596938 wikiPageExternalLink dipra-ir.
- Q19596938 wikiPageWikiLink Q11085.
- Q19596938 wikiPageWikiLink Q1531991.
- Q19596938 wikiPageWikiLink Q1756385.
- Q19596938 wikiPageWikiLink Q18026547.
- Q19596938 wikiPageWikiLink Q18209947.
- Q19596938 wikiPageWikiLink Q21098859.
- Q19596938 wikiPageWikiLink Q2649417.
- Q19596938 wikiPageWikiLink Q30612.
- Q19596938 wikiPageWikiLink Q5443558.
- Q19596938 wikiPageWikiLink Q6535765.
- Q19596938 wikiPageWikiLink Q6589598.
- Q19596938 wikiPageWikiLink Q7180990.
- Q19596938 wikiPageWikiLink Q824258.
- Q19596938 wikiPageWikiLink Q8533689.
- Q19596938 wikiPageWikiLink Q9052323.
- Q19596938 wikiPageWikiLink Q906492.
- Q19596938 atcPrefix "None".
- Q19596938 casNumber "872363".
- Q19596938 iupacName "6".
- Q19596938 pubchem "44557636".
- Q19596938 type ChemicalSubstance.
- Q19596938 type Drug.
- Q19596938 type ChemicalObject.
- Q19596938 type Thing.
- Q19596938 type Q8386.
- Q19596938 comment "Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.".
- Q19596938 label "Dipraglurant".
- Q19596938 depiction Dipraglurant.svg.